Home > Gastroenterology > Adjuvant S-1 therapy superior to observation in resected biliary tract cancer

Adjuvant S-1 therapy superior to observation in resected biliary tract cancer

Presented By
Dr Masafumi Ikeda, Japan Clinical Oncology Group, Japan
Conference
ASCO GI 2022
Trial
Phase 3, JCOG1202, ASCOT
Adjuvant S-1 therapy improved the overall survival (OS) of patients with biliary tract cancer (BTC) who underwent resection via surgery. Also, S-1 therapy was well tolerated in this patient population. Therefore, adjuvant S-1 therapy may be considered as standard-of-care in patients with resected BTC in Japan [1]. “In Japan, capecitabine is currently accepted as the standard adjuvant therapy for patients with curatively resected BTC, despite the fact that no significant OS benefit has been demonstrated of this agent in this population,” Dr Masafumi Ikeda (Japan Clinical Oncology Group, Japan) explained. “In addition, a phase 2 trial demonstrated that S-1, an oral fluoropyrimidine derivative, may provide benefits for patients with advanced BTC [2].” The current phase 3 JCOG1202 ASCOT trial (UMIN000011688) investigated the safety ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on